Nabriva Therapeutics company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

nabriva.com

Founded Year

2006

Stage

IPO | IPO

Total Raised

$142M

Date of IPO

9/18/2015

Market Cap

0.01B

Stock Price

0.18

Revenue

$0000 

About Nabriva Therapeutics

Nabriva Therapeutics (NASDAQ:NBRV) is a biotechnology company focused on developing a class of antibiotics, the pleuromutilins, for the treatment of patients with serious infections caused by multi-drug resistant pathogens.

Nabriva Therapeutics Headquarters Location

Leberstrasse 20

Vienna, 1110,

Austria

+43 (0)1 740 93-0

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Nabriva Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Nabriva Therapeutics is included in 1 Expert Collection, including Biopharma Tech.

B

Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Nabriva Therapeutics Patents

Nabriva Therapeutics has filed 17 patents.

The 3 most popular patent topics include:

  • Microbiology
  • Immune system
  • Immunology
patents chart

Application Date

Grant Date

Title

Related Topics

Status

2/9/2018

2/9/2021

Antibiotics, Ketones, Thioethers, Bacterial diseases, ATC codes

Grant

Application Date

2/9/2018

Grant Date

2/9/2021

Title

Related Topics

Antibiotics, Ketones, Thioethers, Bacterial diseases, ATC codes

Status

Grant

Latest Nabriva Therapeutics News

Nabriva Therapeutics Completes Patient Enrollment in Phase 1 Trial of XENLETA® (lefamulin) in Adult Patients with Cystic Fibrosis

Aug 11, 2022

XENLETA tablets are contraindicated for use with CYP3A4 substrates that prolong the QT interval. WARNINGS AND PRECAUTIONS XENLETA has the potential to prolong the QT interval. Avoid XENLETA in patients with known QT prolongation, ventricular arrhythmias, and patients receiving drugs that may prolong the QT interval. Based on animal studies, XENLETA may cause fetal harm. Advise females of reproductive potential of the potential risk to the fetus and to use effective contraception. Clostridioides difficile-associated diarrhea (CDAD) has been reported with nearly all systemic antibacterial agents, including XENLETA, with severity ranging from mild diarrhea to fatal colitis. Evaluate if diarrhea occurs. ADVERSE REACTIONS The most common adverse reactions (≥2%) for (a) XENLETA Injection are administration site reactions, hepatic enzyme elevation, nausea, hypokalemia, insomnia, and headache and (b) XENLETA Tablets are diarrhea, nausea, vomiting, and hepatic enzyme elevation. USE IN SPECIFIC POPULATIONS In patients with severe hepatic impairment, reduce the dosage of XENLETA Injection to 150 mg infused over 60 minutes every 24 hours. XENLETA Tablets are not recommended in patients with moderate or severe hepatic impairment due to insufficient information to provide dosing recommendations. Avoid XENLETA Injection and Tablets with concomitant strong or moderate CYP3A or P-gp inducers. Monitor for reduced efficacy of XENLETA. Avoid XENLETA Tablets with strong CYP3A or P-gp inhibitors. Monitor for adverse reactions of sensitive CYP3A substrates administered with XENLETA Tablets. XENLETA has not been studied in pregnant women. Verify pregnancy status in females prior to initiating XENLETA and advise females to use contraception during treatment and for 2 days after the final dose. Lactating women should pump and discard milk for the duration of treatment with XENLETA and for 2 days after the final dose. To report SUSPECTED ADVERSE REACTIONS, or administration during pregnancy, contact Nabriva Therapeutics US, Inc. at 1-855-5NABRIVA or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . Forward-Looking Statements Any statements in this press release about future expectations, plans and prospects for Nabriva Therapeutics, including but not limited to statements about the potential of XENLETA to be a treatment option for CF patients with bacterial infections, the timing of dosing, completion and availability of data from the Phase 1 clinical trial of XENLETA, the clinical utility of XENLETA for CABP, SIVEXTRO for ABSSSI and of CONTEPO for cUTI, the impact of macro events on sales of SIVEXTRO and XENLETA, plans for and timing of the review of regulatory filings for XENLETA and CONTEPO, efforts to bring CONTEPO to market, the market opportunity for and the potential market acceptance of XENLETA for CABP, SIVEXTRO for ABSSSI and CONTEPO for cUTI, the development of XENLETA and CONTEPO for additional indications, plans to pursue research and development of other product candidates, expectations regarding the impact of the interruptions resulting from COVID-19 on its business, the sufficiency of Nabriva Therapeutics’ existing cash resources and its expectations regarding anticipated revenues from product sales and how far into the future its existing cash resources will fund its ongoing operations and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “likely,” “will,” “would,” “could,” “should,” “continue,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the content and timing of decisions made by the U.S. Food and Drug Administration and other regulatory authorities, the uncertainties inherent in the initiation and conduct of clinical trials, availability and timing of data from clinical trials, whether results of early clinical trials or studies in different disease indications will be indicative of the results of ongoing or future trials, uncertainties associated with regulatory review of clinical trials and applications for marketing approvals, the availability or commercial potential of CONTEPO for the treatment of cUTI, the extent of business interruptions resulting from the infection causing the COVID-19 outbreak or similar public health crises, the ability to retain and hire key personnel, the availability of adequate additional financing on acceptable terms or at all and such other important factors as are set forth in Nabriva Therapeutics’ annual and quarterly reports and other filings on file with the U.S. Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent Nabriva Therapeutics’ views as of the date of this press release. Nabriva Therapeutics anticipates that subsequent events and developments will cause its views to change. However, while Nabriva Therapeutics may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Nabriva Therapeutics’ views as of any date subsequent to the date of this press release. References Cystic Fibrosis Foundation Patient Registry – Annual Data Report 2018 Dasenbrook EC, et al. JAMA 2010;303(23):2386-2392 CONTACTS:

Nabriva Therapeutics Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Nabriva Therapeutics Rank

  • When was Nabriva Therapeutics founded?

    Nabriva Therapeutics was founded in 2006.

  • Where is Nabriva Therapeutics's headquarters?

    Nabriva Therapeutics's headquarters is located at Leberstrasse 20, Vienna.

  • What is Nabriva Therapeutics's latest funding round?

    Nabriva Therapeutics's latest funding round is IPO.

  • How much did Nabriva Therapeutics raise?

    Nabriva Therapeutics raised a total of $142M.

  • Who are the investors of Nabriva Therapeutics?

    Investors of Nabriva Therapeutics include Novo Ventures, Novartis Venture Funds, Global Life Science Ventures, HBM Partners, EcoR1 Capital and 9 more.

  • Who are Nabriva Therapeutics's competitors?

    Competitors of Nabriva Therapeutics include Arena Pharmaceuticals, Tetraphase Pharmaceuticals, Tarsa Therapeutics, Affinium Pharmaceuticals, Trius Therapeutics and 12 more.

You May Also Like

A
Affinium Pharmaceuticals

Affinium Pharmaceuticals is a specialty pharmaceutical company developing a class of antibiotics that target the bacterial fatty acid synthesis (FASII) pathway. AFN-1252, the company's lead clinical compound, is a highly-potent, small molecule antibiotic for both oral and IV treatment of staphylococcal infections, including MRSA and all other drug-resistant strains.

I
Intarcia Therapeutics

Intarcia Therapeutics is a biopharmaceutical company based in Boston, Massachusetts. Intarcia is engaged in the development of a pipeline of products for the proprietary Medici Drug Delivery System comprised of three technologies: A stabilization technology that allows for proteins, peptides, antibody fragments, and other highly potent small molecules to be stabilized at or above human body temperatures, a matchstick-sized osmotic mini-pump that is placed under the dermal layer of skin to deliver a continuous and consistent flow of medication, and a placement technology including proprietary tools designed to provide an optimal user experience.

I
Inimex Pharmaceuticals

Inimex Pharmaceuticals, Inc. is focused on the development and commercialization of Innate Defense Regulators (IDRs), first in class drugs that selectively trigger the body's innate defenses without causing inflammation. IDR products have major market potential for infectious disease, cancer, and inflammatory disease. These products will reduce morbidity and mortality in the rapidly growing population of immune suppressed and elderly patients who are "at-risk" for these disorders. IDR products will also benefit healthcare payors by reducing costs associated with hospitalization. Inimex' lead IDR product IMX942 targets a broad spectrum of life-threatening hospital infections, many of which are caused by antibiotic-resistant bacteria such as methicillin-resistant Staphylococcus aureus (MRSA) or vancomycin-resistant Enterococcus (VRE). IMX942 is active against both normal and drug-resistant bacteria and its ability to stimulate host innate immune defenses is not susceptible to bacterial antibiotic resistance mechanisms. The first clinical indication for IMX942 will be the prevention of infections associated with cancer chemotherapy-induced immune suppression. nnAdditional IDR product candidates will be developed for distinct disease areas, with an emphasis on inflammatory disease and demonstration of the potential for orally available IDR dosage forms.

L
Lytix Biopharma

Pre clinical developer of lytic peptide drugs for the treatment of resistant bacterial, fungal infections and tumor progression, closed a $10.4M Series D financing. oncology

M
Midway Biome

Midway Biome is a privately-held specialty company located in Philadelphia. Midway was founded by gastrointestinal scientists at the University of Chicago in the Departments of Surgery, Digestive Diseases, Infectious Disease, and an experienced gastroenterologist and biotech entrepreneur. The initial observations leading to products to maintaining health through gut integrity was extended by a scientist in bone physiology at Michigan State University in collaboration with Midway.

O
Oculus Innovative Sciences

Oculus Innovative Sciences develops, manufactures and markets a family of products based upon the Microcyn® Technology platform, which is intended to help prevent and treat infections in chronic and acute wounds. The Microcyn Technology platform features a biocompatible, shelf-stable solution containing active oxychlorine compounds that is currently commercialized in the United States, Europe, India, China and Mexico for the treatment of infected wounds. The solutions derived from this platform have demonstrated, in a variety of research and investigational studies, the ability to treat a wide range of pathogens, including antibiotic-resistant strains of bacteria (including MRSA and VRE), viruses, fungi and spores. The company's headquarters are in Petaluma, California, with operations in Europe and Latin America.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.